The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice

Saideh Fakharzadeh,1 Mohammad Ali Sahraian,2 Maryam Hafizi,1 Somayeh Kalanaky,1 Zahra Masoumi,1 Mehdi Mahdavi,1 Nasser Kamalian,3 Alireza Minagar,4 Mohammad Hassan Nazaran1 1Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 2MS Research Center, Neuroscience Institu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fakharzadeh S, Sahraian MA, Hafizi M, Kalanaky S, Masoumi Z, Mahdavi M, Kamalian N, Minagar A, Nazaran MH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b4db38f86a09482482f681fe063c7afd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4db38f86a09482482f681fe063c7afd
record_format	dspace
spelling	oai:doaj.org-article:b4db38f86a09482482f681fe063c7afd2021-12-02T03:10:57ZThe therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice1178-2013https://doaj.org/article/b4db38f86a09482482f681fe063c7afd2014-08-01T00:00:00Zhttp://www.dovepress.com/the-therapeutic-effects-of-msc1-nanocomplex-synthesized-by-nanochelati-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Saideh Fakharzadeh,1 Mohammad Ali Sahraian,2 Maryam Hafizi,1 Somayeh Kalanaky,1 Zahra Masoumi,1 Mehdi Mahdavi,1 Nasser Kamalian,3 Alireza Minagar,4 Mohammad Hassan Nazaran1 1Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 2MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; 3Department of Pathology, Medical School of Tehran University of Medical Sciences, Tehran, Iran; 4Department of Neurology, LSU Health Sciences Centre, Shreveport, LA, USA Purpose: Currently approved therapies for multiple sclerosis (MS) at best only slow down its progression. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In the present study, for the first time we evaluated the therapeutic potential of MSc1 nanocomplex, which was designed based on novel nanochelating technology. Materials and methods: MSc1 cell-protection capacity, with and without iron bond, was evaluated against hydrogen peroxide (H2O2)-induced oxidative stress in cultured rat pheochromocytoma-12 cells. The ability of MSc1 to maintain iron bond at pH ranges of 1–7 was evaluated. Nanocomplex toxicity was examined by estimating the intraperitoneal median lethal dose (LD50). Experimental autoimmune encephalomyelitic mice were injected with MSc1 14 days after disease induction, when the clinical symptoms appeared. The clinical score, body weight, and disease-induced mortality were monitored until day 54. In the end, after collecting blood samples for assessing hemoglobin and red blood cell count, the brains and livers of the mice were isolated for hematoxylin and eosin staining and analysis of iron content, respectively. Results: The results showed that MSc1 prevented H2O2-induced cell death even after binding with iron, and it preserved its bond with iron constant at pH ranges 1–7. The nanocomplex intraperitoneal LD50 was 1,776.59 mg/kg. MSc1 prompted therapeutic behavior and improved the disabling features of experimental autoimmune encephalomyelitis, which was confirmed by decreased clinical scores versus increased body mass and 100% survival probability. It did not cause any adverse effects on hemoglobin or red blood cell count. Histopathological studies showed no neural loss or lymphocyte infiltration in MSc1-treated mice, while the hepatic iron content was also normal. Conclusion: These results demonstrate that MSc1 could be a promising beneficial novel agent and has the capacity to be evaluated in further studies. Keywords: EAE, multiple sclerosis, MSc1, nanochelating technology, nanocomplexFakharzadeh SSahraian MAHafizi MKalanaky SMasoumi ZMahdavi MKamalian NMinagar ANazaran MHDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 3841-3853 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Fakharzadeh S Sahraian MA Hafizi M Kalanaky S Masoumi Z Mahdavi M Kamalian N Minagar A Nazaran MH The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice
description	Saideh Fakharzadeh,1 Mohammad Ali Sahraian,2 Maryam Hafizi,1 Somayeh Kalanaky,1 Zahra Masoumi,1 Mehdi Mahdavi,1 Nasser Kamalian,3 Alireza Minagar,4 Mohammad Hassan Nazaran1 1Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 2MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; 3Department of Pathology, Medical School of Tehran University of Medical Sciences, Tehran, Iran; 4Department of Neurology, LSU Health Sciences Centre, Shreveport, LA, USA Purpose: Currently approved therapies for multiple sclerosis (MS) at best only slow down its progression. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In the present study, for the first time we evaluated the therapeutic potential of MSc1 nanocomplex, which was designed based on novel nanochelating technology. Materials and methods: MSc1 cell-protection capacity, with and without iron bond, was evaluated against hydrogen peroxide (H2O2)-induced oxidative stress in cultured rat pheochromocytoma-12 cells. The ability of MSc1 to maintain iron bond at pH ranges of 1–7 was evaluated. Nanocomplex toxicity was examined by estimating the intraperitoneal median lethal dose (LD50). Experimental autoimmune encephalomyelitic mice were injected with MSc1 14 days after disease induction, when the clinical symptoms appeared. The clinical score, body weight, and disease-induced mortality were monitored until day 54. In the end, after collecting blood samples for assessing hemoglobin and red blood cell count, the brains and livers of the mice were isolated for hematoxylin and eosin staining and analysis of iron content, respectively. Results: The results showed that MSc1 prevented H2O2-induced cell death even after binding with iron, and it preserved its bond with iron constant at pH ranges 1–7. The nanocomplex intraperitoneal LD50 was 1,776.59 mg/kg. MSc1 prompted therapeutic behavior and improved the disabling features of experimental autoimmune encephalomyelitis, which was confirmed by decreased clinical scores versus increased body mass and 100% survival probability. It did not cause any adverse effects on hemoglobin or red blood cell count. Histopathological studies showed no neural loss or lymphocyte infiltration in MSc1-treated mice, while the hepatic iron content was also normal. Conclusion: These results demonstrate that MSc1 could be a promising beneficial novel agent and has the capacity to be evaluated in further studies. Keywords: EAE, multiple sclerosis, MSc1, nanochelating technology, nanocomplex
format	article
author	Fakharzadeh S Sahraian MA Hafizi M Kalanaky S Masoumi Z Mahdavi M Kamalian N Minagar A Nazaran MH
author_facet	Fakharzadeh S Sahraian MA Hafizi M Kalanaky S Masoumi Z Mahdavi M Kamalian N Minagar A Nazaran MH
author_sort	Fakharzadeh S
title	The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice
title_short	The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice
title_full	The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice
title_fullStr	The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice
title_full_unstemmed	The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice
title_sort	therapeutic effects of msc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic c57/bl6 mice
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/b4db38f86a09482482f681fe063c7afd
work_keys_str_mv	AT fakharzadehs thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT sahraianma thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT hafizim thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT kalanakys thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT masoumiz thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT mahdavim thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT kamaliann thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT minagara thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT nazaranmh thetherapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT fakharzadehs therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT sahraianma therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT hafizim therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT kalanakys therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT masoumiz therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT mahdavim therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT kamaliann therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT minagara therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice AT nazaranmh therapeuticeffectsofmsc1nanocomplexsynthesizedbynanochelatingtechnologyonexperimentalautoimmuneencephalomyeliticc57bl6mice
_version_	1718401941088763904

The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice

Ejemplares similares